SML0650
Risedronate sodium
≥97% (HPLC)
别名:
P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
H2O: 5 mg/mL, clear (warmed)
storage temp.
room temp
SMILES string
[Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
InChI
1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
InChI key
DRFDPXKCEWYIAW-UHFFFAOYSA-M
Biochem/physiol Actions
Risedronate sodium is a bisphosphonate bone resorption inhibitor.
Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Seiji Ohtori et al.
Spine, 38(8), E487-E492 (2013-01-29)
Prospective study. To examine the efficacy of teriparatide or bisphosphonate treatment to reduce pedicle screw (PS) loosening after instrumented lumbar posterolateral fusion in postmenopausal women with osteoporosis. Failure of fixation caused by loosening of PSs in osteoporosis is a problem
Y Sato et al.
Journal of musculoskeletal & neuronal interactions, 13(3), 346-352 (2013-08-31)
Minodronate is a nitrogen-containing bisphosphonate that is commercially available for the treatment of osteoporosis in Japan. Preclinical studies demonstrated that minodronate is at least 10 times more potent than alendronate in inhibiting bone resorption in vivo. A high incidence of
J B Matheny et al.
Bone, 57(1), 277-283 (2013-08-31)
Alterations in resorption cavities and bone remodeling events during anti-resorptive treatment are believed to contribute to reductions in fracture risk. Here, we examine changes in the size of individual remodeling events associated with treatment with a selective estrogen receptor modulator
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0650-50MG | 04061837101205 |